AstraZeneca in Talks for Potential $300 Billion Merger with Bristol Myers Squibb

AstraZeneca has reportedly held discussions with its U.S. rival Bristol Myers Squibb regarding a potential merger that could value the combined entity at over £300 billion. Such a deal would establish a new global pharmaceutical powerhouse, ranking as the fourth largest in the industry.

While reports suggest that discussions have taken place in recent months, the Financial Times noted that the deal "may be delayed or fall apart." A potential merger comes as AstraZeneca, a major British firm, seeks to expand its presence in the crucial U.S. market. The company completed an additional listing on the New York Stock Exchange in July, as part of Chief Executive Pascal Soriot's strategy to increase the company's U.S. market share.

AstraZeneca, based in Cambridge, England, is the United Kingdom's second most valuable company with a market capitalization around £196 billion. New York-listed Bristol Myers Squibb, which focuses on cardiovascular and oncology treatments, is currently valued at approximately £133 billion.

Any proposed merger would likely face significant scrutiny from competition and antitrust regulators, particularly in the United States, where the Trump administration has increased its focus on domestic investment and scrutinizing the sector. This potential deal also adds to ongoing concerns about prominent British firms potentially exiting the UK market.

Despite these discussions, Soriot stated last week that AstraZeneca does not "need M&A to deliver" on its 2030 revenue targets. Analysts, however, note that companies sometimes pursue acquisitions even after publicly stating they do not require them. The combination of the two companies' large oncology divisions is also seen as a potential hurdle for regulatory approval.